The U.S. Centers for Disease Control and Prevention published research in the journal Lancet Infectious Diseases outlining the results from two experimental Ebola drugs, Gilead Sciences’ remdesivir and Mapp Biopharmaceutical’s ZMapp.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,